Rock Springs Capital Management LP's Net Worth
-$9.43 Million
Who is Rock Springs Capital Management LP?
Rock Springs Capital Management LP does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Atea Pharmaceuticals, Inc., Nivalis Therapeutics, Inc., Theseus Pharmaceuticals, Inc., Verve Therapeutics, Inc., Xilio Therapeutics, Inc., Inozyme Pharma, Inc., Cerulean Pharma Inc., Tempest Therapeutics, Inc., Homology Medicines, Inc., and IMARA Inc..
SEC CIK
Rock Springs Capital Management LP's CIK is 0001595725
Past Insider Trading and Trends
2020 was Rock Springs Capital Management LP's most active year for acquiring shares with 9 total transactions. Rock Springs Capital Management LP's most active month to acquire stocks was the month of September. 2020 was Rock Springs Capital Management LP's most active year for disposing of shares, totalling 6 transactions. Rock Springs Capital Management LP's most active month to dispose stocks was the month of September. 2020 saw Rock Springs Capital Management LP paying a total of $19,600,000.00 for 3,535,714 shares, this is the most they've acquired in one year. In 2021 Rock Springs Capital Management LP cashed out on 15,627,502 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Atea Pharmaceuticals, Inc. (AVIR) Snapshot price: $4.3
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +114.75% | 1.94M |
$24.00 | $6,000,000.00 | 3.64M |
Nov 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Nivalis Therapeutics, Inc. (ALPN) Snapshot price: $27.21
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 564.36K |
$14.00 |
—
| 564.36K |
Jun 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Theseus Pharmaceuticals, Inc. (THRX) Snapshot price: $4.1
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +196.57% | 686.65K |
$16.00 | $4,000,000.00 | 1.04M |
Oct 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Verve Therapeutics, Inc. (VERV) Snapshot price: $10.995
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.08M |
$19.00 |
—
| 1.08M |
Jun 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.6382
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +186.10% | 1.41M |
$16.00 | $8,000,000.00 | 2.16M |
Oct 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||